Literature DB >> 12775769

Breast cancer: when proteomics challenges biological complexity.

Hubert Hondermarck1.   

Abstract

Proteomics is now entering into the field of biomedicine with declared hopes for the identification of new pathological markers and therapeutic targets. Current proteomic tools allow large-scale, high-throughput analyses for the detection, identification, and functional investigation of low-abundant proteins. However, the major limitation of proteomic investigations remains the complexity of biological structures and physiological processes, rendering the path of exploration of related pathologies paved with various difficulties and pitfalls. The case of breast cancer illustrates the major challenge facing modern proteomics and more generally post-genomics: to tackle the complexity of life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775769     DOI: 10.1074/mcp.R300003-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  20 in total

1.  "Proteotyping": population proteomics of human leukocytes using top down mass spectrometry.

Authors:  Michael J Roth; Bryan A Parks; Jonathan T Ferguson; Michael T Boyne; Neil L Kelleher
Journal:  Anal Chem       Date:  2008-03-20       Impact factor: 6.986

2.  CanProVar: a human cancer proteome variation database.

Authors:  Jing Li; Dexter T Duncan; Bing Zhang
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

Review 3.  Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.

Authors:  Sayem Miah; Charles A S Banks; Mark K Adams; Laurence Florens; Kiven E Lukong; Michael P Washburn
Journal:  Mol Biosyst       Date:  2016-12-20

4.  In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology.

Authors:  Sangwon Cha; Marcin B Imielinski; Tomas Rejtar; Elizabeth A Richardson; Dipak Thakur; Dennis C Sgroi; Barry L Karger
Journal:  Mol Cell Proteomics       Date:  2010-08-25       Impact factor: 5.911

5.  Expression of the molecular chaperone αB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy.

Authors:  Maria Kabbage; Mounir Trimeche; Hela Ben Nasr; Philippe Hammann; Lauriane Kuhn; Bechr Hamrita; Anouar Chaieb; Lotfi Chouchane; Karim Chahed
Journal:  Tumour Biol       Date:  2012-09-13

Review 6.  What does physics have to do with cancer?

Authors:  Franziska Michor; Jan Liphardt; Mauro Ferrari; Jonathan Widom
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

7.  Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling.

Authors:  Yogesh M Kulkarni; Vivian Suarez; David J Klinke
Journal:  BMC Cancer       Date:  2010-06-15       Impact factor: 4.430

8.  Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses.

Authors:  Maria Kabbage; Mounir Trimeche; Sarra Bergaoui; Philippe Hammann; Lauriane Kuhn; Bechr Hamrita; Hela ben Nasr; Anouar Chaieb; Lotfi Chouchane; Karim Chahed
Journal:  Tumour Biol       Date:  2013-01-22

Review 9.  Cancer proteomics by quantitative shotgun proteomics.

Authors:  Emily I Chen; John R Yates
Journal:  Mol Oncol       Date:  2007-09       Impact factor: 6.603

10.  Transcriptional activation of insulin-like growth factor binding protein 6 by 17beta-estradiol in SaOS-2 cells.

Authors:  Yu-yan Zhao; Lei Guo; Xiao-juan Zhao; Hong Liu; Tian Lei; Dong-jie Ma; Xiao-yu Gao
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.